The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to tinostamustine, an investigational therapeutic from Purdue Pharma L.P., for the treatment of patients with malignant ...

A new research paper was published in Oncotarget (Volume 16) on November 6, 2025, titled "LRIG1-3 in gliomas: LRIG1 protein ...

Glioblastoma—the most aggressive form of brain cancer—remains one of medicine's biggest challenges. Despite surgery, ...

When University of Virginia neuroscientist Harald Sontheimer shared this year’s International Prize for Translational ...

Clinician-scientists at St. Jude Children's Research Hospital and collaborators have conducted the largest study of ...

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will present five abstracts at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting taking place November 19-23 in Honolulu ...

Gliomas are the most prevalent and aggressive primary brain tumors, characterized by profound tumor heterogeneity, poor prognosis, and limited therapeutic ...

Glioblastoma is one of the most aggressive and complex brain cancers. It grows quickly, resists standard treatments, and ...

Project Rocket is a labor of love and legacy. With help from the community, last year, one local family raised over $30,000 ...

"We were going to lose our beautiful five-year-old daughter, and there was nothing anyone could do to stop it," Ms Giles said ...

Chordoid glioma of the third ventricle is a rare primary central nervous system tumour that poses significant diagnostic and therapeutic challenges. Initially described in the late 1990s, these ...